 | • レポートコード：QY2108PAL8803 • 出版社/出版日：QYResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、144ページ • 納品方法：Eメール（納期：1日） • 産業分類：医薬品 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の当調査資料ではグローバルにおける皮膚リーシュマニア症治療薬の市場規模（2016年-2027年）と動向についてまとめました。中国市場については主要プレイヤーの市場シェア、皮膚リーシュマニア症治療薬の種類別市場規模（5価アンチモニアル、抗真菌薬、抗リーシュマニア/抗菌薬）、用途別市場規模（病院、小売薬局、その他）も掲載しています。他に、北米・アメリカ市場、ヨーロッパ市場、アジア太平洋・日本市場、中南米市場、中東・アフリカ市場の市場規模、グローバル市場機会・課題・リスク要因、バリューチェーン・販売チャネル、主要プレイヤーの情報なども掲載しています。 ・調査の概要 ・調査のサマリー ・世界の皮膚リーシュマニア症治療薬市場動向 ・グローバル主要プレイヤーの競争状況・市場シェア ・世界における皮膚リーシュマニア症治療薬の種類別市場規模（2016年-2027年）：5価アンチモニアル、抗真菌薬、抗リーシュマニア/抗菌薬 ・世界における皮膚リーシュマニア症治療薬の用途別市場規模（2016年-2027年）：病院、小売薬局、その他 ・皮膚リーシュマニア症治療薬の中国市場分析 - 皮膚リーシュマニア症治療薬の中国市場規模（2016年-2027年） - 中国における皮膚リーシュマニア症治療薬の主要プレイヤー別市場シェア - 中国における皮膚リーシュマニア症治療薬の種類別市場規模：5価アンチモニアル、抗真菌薬、抗リーシュマニア/抗菌薬 - 中国における皮膚リーシュマニア症治療薬の用途別市場規模：病院、小売薬局、その他 ・皮膚リーシュマニア症治療薬の北米市場（2016年-2027年） ・皮膚リーシュマニア症治療薬のヨーロッパ市場（2016年-2027年） ・皮膚リーシュマニア症治療薬のアジア太平洋市場（2016年-2027年） ・皮膚リーシュマニア症治療薬の中南米市場（2016年-2027年） ・皮膚リーシュマニア症治療薬の中東・アフリカ市場（2016年-2027年） ・主要プレイヤーの情報：GSK、Novartis、Sanofi、Gilead Sciences、Bristol-Myers Squibb、Albert David、Profounda、Knight Therapeutics、Pfizer、Xinhua Pharma ・市場機会・課題・リスク要因分析 ・バリューチェーン・販売チャネル分析 ・... |
Cutaneous leishmaniasis is the most common syndrome and can produce ulcers that have the potential of stimulating a periosteal reaction if the ulcer occurs near bone.
Leishmaniasis, a protozoal infection transmitted by sandfly bite, produces a clinical spectrum of disease ranging from asymptomatic infection to ulcerative skin and mucosal lesions to visceral involvement. Leishmaniasis is endemic in regions of Africa, the Middle East, south Asia, southern Europe, northern South America, and Central America. There has been an increase in imported leishmaniasis into developed, non-endemic countries due to increasing global travel. While pentavalent antimonials have been the mainstay of antileishmanial treatment for decades, newer therapeutic options have become available for all forms of infection, including liposomal amphotericin B, miltefosine, fluconazole, and ketoconazole.
Global Cutaneous Leishmaniasis Drugs Sales key players include Sanofi, Albert David, Albert David, etc. Global top three manufacturers hold a share over 60%. Middle East and Africa is the largest market, with a share about 40%, followed by Asia-Pacific, and South America. In terms of product, Pentavalent Antimonials is the largest segment, with a share over 43%. In Cutaneous Leishmaniasis Drugs market, the Hospital holds an important share in terms of Application, followed by Retail Pharmacy, etc.
Market Analysis and Insights: Global and China Cutaneous Leishmaniasis Drugs Market
This report focuses on global and China Cutaneous Leishmaniasis Drugs market.
In 2020, the global Cutaneous Leishmaniasis Drugs market size was US$ 41 million and it is expected to reach US$ 55 million by the end of 2027, with a CAGR of 4.1% during 2021-2027. In China the Cutaneous Leishmaniasis Drugs market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.
Global Cutaneous Leishmaniasis Drugs Scope and Market Size
Cutaneous Leishmaniasis Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Cutaneous Leishmaniasis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Cutaneous Leishmaniasis Drugs market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.
Segment by Type
Pentavalent Antimonials
Antifungal Drugs
Anti-Leishmanial/Antimicrobial Drugs
Segment by Application
Hospital
Retail Pharmacy
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
GSK
Novartis
Sanofi
Gilead Sciences
Bristol-Myers Squibb
Albert David
Profounda
Knight Therapeutics
Pfizer
Xinhua Pharma
1 Study Coverage
1.1 Cutaneous Leishmaniasis Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Cutaneous Leishmaniasis Drugs Market Size Growth Rate by Type
1.2.2 Pentavalent Antimonials
1.2.3 Antifungal Drugs
1.2.4 Anti-Leishmanial/Antimicrobial Drugs
1.3 Market by Application
1.3.1 Global Cutaneous Leishmaniasis Drugs Market Size Growth Rate by Application
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Cutaneous Leishmaniasis Drugs Market Size, Estimates and Forecasts
2.1.1 Global Cutaneous Leishmaniasis Drugs Revenue 2016-2027
2.1.2 Global Cutaneous Leishmaniasis Drugs Sales 2016-2027
2.2 Global Cutaneous Leishmaniasis Drugs, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Cutaneous Leishmaniasis Drugs Historical Market Size by Region (2016-2021)
2.3.1 Global Cutaneous Leishmaniasis Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Cutaneous Leishmaniasis Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Cutaneous Leishmaniasis Drugs Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Cutaneous Leishmaniasis Drugs Sales Forecast by Region (2022-2027)
2.4.2 Global Cutaneous Leishmaniasis Drugs Revenue Forecast by Region (2022-2027)
3 Global Cutaneous Leishmaniasis Drugs Competitor Landscape by Players
3.1 Global Top Cutaneous Leishmaniasis Drugs Manufacturers by Sales
3.1.1 Global Cutaneous Leishmaniasis Drugs Sales by Manufacturer (2016-2021)
3.1.2 Global Cutaneous Leishmaniasis Drugs Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Cutaneous Leishmaniasis Drugs Manufacturers by Revenue
3.2.1 Key Cutaneous Leishmaniasis Drugs Manufacturers Covered: Ranking by Revenue
3.2.2 Global Cutaneous Leishmaniasis Drugs Revenue by Manufacturers (2016-2021)
3.2.3 Global Cutaneous Leishmaniasis Drugs Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Cutaneous Leishmaniasis Drugs Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Cutaneous Leishmaniasis Drugs Revenue in 2020
3.2.6 Global Cutaneous Leishmaniasis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Cutaneous Leishmaniasis Drugs Price by Manufacturers
3.4 Global Cutaneous Leishmaniasis Drugs Manufacturing Base Distribution, Product Types
3.4.1 Cutaneous Leishmaniasis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cutaneous Leishmaniasis Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Cutaneous Leishmaniasis Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Cutaneous Leishmaniasis Drugs Market Size by Type (2016-2021)
4.1.1 Global Cutaneous Leishmaniasis Drugs Sales by Type (2016-2021)
4.1.2 Global Cutaneous Leishmaniasis Drugs Revenue by Type (2016-2021)
4.1.3 Cutaneous Leishmaniasis Drugs Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Cutaneous Leishmaniasis Drugs Market Size Forecast by Type (2022-2027)
4.2.1 Global Cutaneous Leishmaniasis Drugs Sales Forecast by Type (2022-2027)
4.2.2 Global Cutaneous Leishmaniasis Drugs Revenue Forecast by Type (2022-2027)
4.2.3 Cutaneous Leishmaniasis Drugs Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Cutaneous Leishmaniasis Drugs Market Size by Application (2016-2021)
5.1.1 Global Cutaneous Leishmaniasis Drugs Sales by Application (2016-2021)
5.1.2 Global Cutaneous Leishmaniasis Drugs Revenue by Application (2016-2021)
5.1.3 Cutaneous Leishmaniasis Drugs Price by Application (2016-2021)
5.2 Cutaneous Leishmaniasis Drugs Market Size Forecast by Application (2022-2027)
5.2.1 Global Cutaneous Leishmaniasis Drugs Sales Forecast by Application (2022-2027)
5.2.2 Global Cutaneous Leishmaniasis Drugs Revenue Forecast by Application (2022-2027)
5.2.3 Global Cutaneous Leishmaniasis Drugs Price Forecast by Application (2022-2027)
6 China by Players, Type and Application
6.1 China Cutaneous Leishmaniasis Drugs Market Size YoY Growth 2016-2027
6.1.1 China Cutaneous Leishmaniasis Drugs Sales YoY Growth 2016-2027
6.1.2 China Cutaneous Leishmaniasis Drugs Revenue YoY Growth 2016-2027
6.1.3 China Cutaneous Leishmaniasis Drugs Market Share in Global Market 2016-2027
6.2 China Cutaneous Leishmaniasis Drugs Market Size by Players (International and Local Players)
6.2.1 China Top Cutaneous Leishmaniasis Drugs Players by Sales (2016-2021)
6.2.2 China Top Cutaneous Leishmaniasis Drugs Players by Revenue (2016-2021)
6.3 China Cutaneous Leishmaniasis Drugs Historic Market Review by Type (2016-2021)
6.3.1 China Cutaneous Leishmaniasis Drugs Sales Market Share by Type (2016-2021)
6.3.2 China Cutaneous Leishmaniasis Drugs Revenue Market Share by Type (2016-2021)
6.3.3 China Cutaneous Leishmaniasis Drugs Price by Type (2016-2021)
6.4 China Cutaneous Leishmaniasis Drugs Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Cutaneous Leishmaniasis Drugs Sales Forecast by Type (2022-2027)
6.4.2 China Cutaneous Leishmaniasis Drugs Revenue Forecast by Type (2022-2027)
6.4.3 China Cutaneous Leishmaniasis Drugs Price Forecast by Type (2022-2027)
6.5 China Cutaneous Leishmaniasis Drugs Historic Market Review by Application (2016-2021)
6.5.1 China Cutaneous Leishmaniasis Drugs Sales Market Share by Application (2016-2021)
6.5.2 China Cutaneous Leishmaniasis Drugs Revenue Market Share by Application (2016-2021)
6.5.3 China Cutaneous Leishmaniasis Drugs Price by Application (2016-2021)
6.6 China Cutaneous Leishmaniasis Drugs Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Cutaneous Leishmaniasis Drugs Sales Forecast by Application (2022-2027)
6.6.2 China Cutaneous Leishmaniasis Drugs Revenue Forecast by Application (2022-2027)
6.6.3 China Cutaneous Leishmaniasis Drugs Price Forecast by Application (2022-2027)
7 North America
7.1 North America Cutaneous Leishmaniasis Drugs Market Size YoY Growth 2016-2027
7.2 North America Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
7.2.1 North America Cutaneous Leishmaniasis Drugs Sales by Country (2016-2021)
7.2.2 North America Cutaneous Leishmaniasis Drugs Revenue by Country (2016-2021)
7.2.3 United States
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Cutaneous Leishmaniasis Drugs Market Size YoY Growth 2016-2027
8.2 Asia Pacific Cutaneous Leishmaniasis Drugs Market Facts & Figures by Region
8.2.1 Asia Pacific Cutaneous Leishmaniasis Drugs Sales by Region (2016-2021)
8.2.2 Asia Pacific Cutaneous Leishmaniasis Drugs Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
9 Europe
9.1 Europe Cutaneous Leishmaniasis Drugs Market Size YoY Growth 2016-2027
9.2 Europe Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
9.2.1 Europe Cutaneous Leishmaniasis Drugs Sales by Country (2016-2021)
9.2.2 Europe Cutaneous Leishmaniasis Drugs Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Cutaneous Leishmaniasis Drugs Market Size YoY Growth 2016-2027
10.2 Latin America Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
10.2.1 Latin America Cutaneous Leishmaniasis Drugs Sales by Country (2016-2021)
10.2.2 Latin America Cutaneous Leishmaniasis Drugs Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
10.2.6 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Cutaneous Leishmaniasis Drugs Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Cutaneous Leishmaniasis Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Cutaneous Leishmaniasis Drugs Sales by Country (2016-2021)
11.2.2 Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 UAE
12 Company Profiles
12.1 GSK
12.1.1 GSK Corporation Information
12.1.2 GSK Description and Business Overview
12.1.3 GSK Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.1.4 GSK Cutaneous Leishmaniasis Drugs Products Offered
12.1.5 GSK Recent Development
12.2 Novartis
12.2.1 Novartis Corporation Information
12.2.2 Novartis Description and Business Overview
12.2.3 Novartis Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Novartis Cutaneous Leishmaniasis Drugs Products Offered
12.2.5 Novartis Recent Development
12.3 Sanofi
12.3.1 Sanofi Corporation Information
12.3.2 Sanofi Description and Business Overview
12.3.3 Sanofi Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Sanofi Cutaneous Leishmaniasis Drugs Products Offered
12.3.5 Sanofi Recent Development
12.4 Gilead Sciences
12.4.1 Gilead Sciences Corporation Information
12.4.2 Gilead Sciences Description and Business Overview
12.4.3 Gilead Sciences Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Gilead Sciences Cutaneous Leishmaniasis Drugs Products Offered
12.4.5 Gilead Sciences Recent Development
12.5 Bristol-Myers Squibb
12.5.1 Bristol-Myers Squibb Corporation Information
12.5.2 Bristol-Myers Squibb Description and Business Overview
12.5.3 Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Products Offered
12.5.5 Bristol-Myers Squibb Recent Development
12.6 Albert David
12.6.1 Albert David Corporation Information
12.6.2 Albert David Description and Business Overview
12.6.3 Albert David Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Albert David Cutaneous Leishmaniasis Drugs Products Offered
12.6.5 Albert David Recent Development
12.7 Profounda
12.7.1 Profounda Corporation Information
12.7.2 Profounda Description and Business Overview
12.7.3 Profounda Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Profounda Cutaneous Leishmaniasis Drugs Products Offered
12.7.5 Profounda Recent Development
12.8 Knight Therapeutics
12.8.1 Knight Therapeutics Corporation Information
12.8.2 Knight Therapeutics Description and Business Overview
12.8.3 Knight Therapeutics Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Knight Therapeutics Cutaneous Leishmaniasis Drugs Products Offered
12.8.5 Knight Therapeutics Recent Development
12.9 Pfizer
12.9.1 Pfizer Corporation Information
12.9.2 Pfizer Description and Business Overview
12.9.3 Pfizer Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Pfizer Cutaneous Leishmaniasis Drugs Products Offered
12.9.5 Pfizer Recent Development
12.10 Xinhua Pharma
12.10.1 Xinhua Pharma Corporation Information
12.10.2 Xinhua Pharma Description and Business Overview
12.10.3 Xinhua Pharma Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Xinhua Pharma Cutaneous Leishmaniasis Drugs Products Offered
12.10.5 Xinhua Pharma Recent Development
12.11 GSK
12.11.1 GSK Corporation Information
12.11.2 GSK Description and Business Overview
12.11.3 GSK Cutaneous Leishmaniasis Drugs Sales, Revenue and Gross Margin (2016-2021)
12.11.4 GSK Cutaneous Leishmaniasis Drugs Products Offered
12.11.5 GSK Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Cutaneous Leishmaniasis Drugs Industry Trends
13.2 Cutaneous Leishmaniasis Drugs Market Drivers
13.3 Cutaneous Leishmaniasis Drugs Market Challenges
13.4 Cutaneous Leishmaniasis Drugs Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cutaneous Leishmaniasis Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Global Cutaneous Leishmaniasis Drugs Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Pentavalent Antimonials
Table 3. Major Manufacturers of Antifungal Drugs
Table 4. Major Manufacturers of Anti-Leishmanial/Antimicrobial Drugs
Table 5. Global Cutaneous Leishmaniasis Drugs Market Size Growth Rate by Application (2021-2027) & (K Units)
Table 6. Global Cutaneous Leishmaniasis Drugs Market Size by Region (K Units) & (US$ Million), 2016 VS 2021 VS 2027
Table 7. Global Cutaneous Leishmaniasis Drugs Sales by Regions (2016-2021) & (K Units)
Table 8. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Regions (2016-2021)
Table 9. Global Cutaneous Leishmaniasis Drugs Revenue by Regions (2016-2021) & (US$ Million)
Table 10. Global Cutaneous Leishmaniasis Drugs Sales Forecast by Region (2022-2027) & (K Units)
Table 11. Global Cutaneous Leishmaniasis Drugs Sales Market Share Forecast by Region (2022-2027)
Table 12. Global Cutaneous Leishmaniasis Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 13. Global Cutaneous Leishmaniasis Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 14. Global Cutaneous Leishmaniasis Drugs Sales by Manufacturers (2016-2021) (K Units)
Table 15. Global Cutaneous Leishmaniasis Drugs Sales Share by Manufacturers (2016-2021)
Table 16. Ranking of Global Top Cutaneous Leishmaniasis Drugs Manufacturers by Revenue (US$ Million) in 2020
Table 17. Cutaneous Leishmaniasis Drugs Revenue by Manufacturers (2016-2021) (US$ Million)
Table 18. Cutaneous Leishmaniasis Drugs Revenue Share by Manufacturers (2016-2021)
Table 19. Global Cutaneous Leishmaniasis Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 20. Global Cutaneous Leishmaniasis Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cutaneous Leishmaniasis Drugs as of 2020)
Table 21. Key Manufacturers Cutaneous Leishmaniasis Drugs Price (2016-2021) (US$/Unit)
Table 22. Cutaneous Leishmaniasis Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Cutaneous Leishmaniasis Drugs Product Type
Table 24. Date of International Manufacturers Enter into Cutaneous Leishmaniasis Drugs Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Cutaneous Leishmaniasis Drugs Sales by Type (2016-2021) (K Units)
Table 27. Global Cutaneous Leishmaniasis Drugs Sales Share by Type (2016-2021)
Table 28. Global Cutaneous Leishmaniasis Drugs Revenue by Type (2016-2021) (US$ Million)
Table 29. Global Cutaneous Leishmaniasis Drugs Revenue Share by Type (2016-2021)
Table 30. Cutaneous Leishmaniasis Drugs Average Selling Price (ASP) by Type (2016-2021) & (US$/Unit)
Table 31. Global Cutaneous Leishmaniasis Drugs Sales Forecast by Type (2022-2027) & (K Units)
Table 32. Global Cutaneous Leishmaniasis Drugs Sales Market Share Forecast by Type (2022-2027)
Table 33. Global Cutaneous Leishmaniasis Drugs Revenue Forecast V (2022-2027) & (US$ Million)
Table 34. Global Cutaneous Leishmaniasis Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 35. Global Cutaneous Leishmaniasis Drugs Average Selling Price (ASP) Forecast by Type (2022-2027) & (US$/Unit)
Table 36. Global Cutaneous Leishmaniasis Drugs Sales by Application (2016-2021) (K Units)
Table 37. Global Cutaneous Leishmaniasis Drugs Sales Share by Application (2016-2021)
Table 38. Global Cutaneous Leishmaniasis Drugs Revenue by Application (2016-2021) (US$ Million)
Table 39. Global Cutaneous Leishmaniasis Drugs Revenue Share by Application (2016-2021)
Table 40. Cutaneous Leishmaniasis Drugs Average Selling Price (ASP) by Application (2016-2021) & (US$/Unit)
Table 41. Global Cutaneous Leishmaniasis Drugs Sales Forecast by Application (2022-2027) & (K Units)
Table 42. Global Cutaneous Leishmaniasis Drugs Sales Market Share Forecast by Application (2022-2027)
Table 43. Global Cutaneous Leishmaniasis Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 44. Global Cutaneous Leishmaniasis Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 45. Global Cutaneous Leishmaniasis Drugs Average Selling Price (ASP) Forecast by Application (2022-2027) & (US$/Unit)
Table 46. China Cutaneous Leishmaniasis Drugs Sales (K Units) of Key Companies (2016-2021)
Table 47. China Cutaneous Leishmaniasis Drugs Sales Share by Company (2016-2021)
Table 48. China Cutaneous Leishmaniasis Drugs Revenue (US$ Million) by Company (2016-2021)
Table 49. China Cutaneous Leishmaniasis Drugs Revenue Share by Company (2016-2021)
Table 50. China Cutaneous Leishmaniasis Drugs Sales (K Units) by Type (2016-2021)
Table 51. China Cutaneous Leishmaniasis Drugs Sales Share by Type (2016-2021)
Table 52. China Cutaneous Leishmaniasis Drugs Revenue (US$ Million) Market Share by Type (2016-2021)
Table 53. China Cutaneous Leishmaniasis Drugs Price (US$/Unit) by Type (2016-2021)
Table 54. China Cutaneous Leishmaniasis Drugs Sales (K Units) by Type (2022-2027)
Table 55. China Cutaneous Leishmaniasis Drugs Sales Share by Type (2022-2027)
Table 56. China Cutaneous Leishmaniasis Drugs Revenue (US$ Million) Market Share by Type (2022-2027)
Table 57. China Cutaneous Leishmaniasis Drugs Revenue Share by Type (2022-2027)
Table 58. China Cutaneous Leishmaniasis Drugs Price (US$/Unit) by Type (2022-2027)
Table 59. China Cutaneous Leishmaniasis Drugs Sales (K Units) by Application (2016-2021)
Table 60. China Cutaneous Leishmaniasis Drugs Sales Share by Application (2016-2021)
Table 61. China Cutaneous Leishmaniasis Drugs Revenue (US$ Million) Market Share by Application (2016-2021)
Table 62. China Cutaneous Leishmaniasis Drugs Price (US$/Unit) by Application (2016-2021)
Table 63. China Cutaneous Leishmaniasis Drugs Sales (K Units) by Application (2022-2027)
Table 64. China Cutaneous Leishmaniasis Drugs Sales Share by Application (2022-2027)
Table 65. China Cutaneous Leishmaniasis Drugs Revenue (US$ Million) Market Share by Application (2022-2027)
Table 66. China Cutaneous Leishmaniasis Drugs Revenue Share by Application (2022-2027)
Table 67. China Cutaneous Leishmaniasis Drugs Price (US$/Unit) by Application (2022-2027)
Table 68. North America Cutaneous Leishmaniasis Drugs Sales by Country (2016-2021) & (K Units)
Table 69. North America Cutaneous Leishmaniasis Drugs Sales Market Share by Country (2016-2021)
Table 70. North America Cutaneous Leishmaniasis Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 71. North America Cutaneous Leishmaniasis Drugs Revenue Market Share by Country (2016-2021)
Table 72. Asia Pacific Cutaneous Leishmaniasis Drugs Sales by Region (2016-2021) & (K Units)
Table 73. Asia Pacific Cutaneous Leishmaniasis Drugs Sales Market Share by Region (2016-2021)
Table 74. Asia Pacific Cutaneous Leishmaniasis Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 75. Asia Pacific Cutaneous Leishmaniasis Drugs Revenue Market Share by Region (2016-2021)
Table 76. Europe Cutaneous Leishmaniasis Drugs Sales by Country (2016-2021) & (K Units)
Table 77. Europe Cutaneous Leishmaniasis Drugs Sales Market Share by Country (2016-2021)
Table 78. Europe Cutaneous Leishmaniasis Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 79. Europe Cutaneous Leishmaniasis Drugs Revenue Market Share by Country (2016-2021)
Table 80. Latin America Cutaneous Leishmaniasis Drugs Sales by Country (2016-2021) & (K Units)
Table 81. Latin America Cutaneous Leishmaniasis Drugs Sales Market Share by Country (2016-2021)
Table 82. Latin Americaa Cutaneous Leishmaniasis Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 83. Latin America Cutaneous Leishmaniasis Drugs Revenue Market Share by Country (2016-2021)
Table 84. Middle East and Africa Cutaneous Leishmaniasis Drugs Sales by Country (2016-2021) & (K Units)
Table 85. Middle East and Africa Cutaneous Leishmaniasis Drugs Sales Market Share by Country (2016-2021)
Table 86. Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 87. Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue Market Share by Country (2016-2021)
Table 88. GSK Corporation Information
Table 89. GSK Description and Business Overview
Table 90. GSK Cutaneous Leishmaniasis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. GSK Cutaneous Leishmaniasis Drugs Product
Table 92. GSK Recent Development
Table 93. Novartis Corporation Information
Table 94. Novartis Description and Business Overview
Table 95. Novartis Cutaneous Leishmaniasis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 96. Novartis Product
Table 97. Novartis Recent Development
Table 98. Sanofi Corporation Information
Table 99. Sanofi Description and Business Overview
Table 100. Sanofi Cutaneous Leishmaniasis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 101. Sanofi Product
Table 102. Sanofi Recent Development
Table 103. Gilead Sciences Corporation Information
Table 104. Gilead Sciences Description and Business Overview
Table 105. Gilead Sciences Cutaneous Leishmaniasis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 106. Gilead Sciences Product
Table 107. Gilead Sciences Recent Development
Table 108. Bristol-Myers Squibb Corporation Information
Table 109. Bristol-Myers Squibb Description and Business Overview
Table 110. Bristol-Myers Squibb Cutaneous Leishmaniasis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 111. Bristol-Myers Squibb Product
Table 112. Bristol-Myers Squibb Recent Development
Table 113. Albert David Corporation Information
Table 114. Albert David Description and Business Overview
Table 115. Albert David Cutaneous Leishmaniasis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 116. Albert David Product
Table 117. Albert David Recent Development
Table 118. Profounda Corporation Information
Table 119. Profounda Description and Business Overview
Table 120. Profounda Cutaneous Leishmaniasis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 121. Profounda Product
Table 122. Profounda Recent Development
Table 123. Knight Therapeutics Corporation Information
Table 124. Knight Therapeutics Description and Business Overview
Table 125. Knight Therapeutics Cutaneous Leishmaniasis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 126. Knight Therapeutics Product
Table 127. Knight Therapeutics Recent Development
Table 128. Pfizer Corporation Information
Table 129. Pfizer Description and Business Overview
Table 130. Pfizer Cutaneous Leishmaniasis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 131. Pfizer Product
Table 132. Pfizer Recent Development
Table 133. Xinhua Pharma Corporation Information
Table 134. Xinhua Pharma Description and Business Overview
Table 135. Xinhua Pharma Cutaneous Leishmaniasis Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 136. Xinhua Pharma Product
Table 137. Xinhua Pharma Recent Development
Table 138. Cutaneous Leishmaniasis Drugs Market Trends
Table 139. Cutaneous Leishmaniasis Drugs Market Drivers
Table 140. Cutaneous Leishmaniasis Drugs Market Challenges
Table 141. Cutaneous Leishmaniasis Drugs Market Restraints
Table 142. Cutaneous Leishmaniasis Drugs Customers List
Table 143. Cutaneous Leishmaniasis Drugs Distributors List
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Cutaneous Leishmaniasis Drugs Product Picture
Figure 2. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Type in 2020 & 2027
Figure 3. Pentavalent Antimonials Product Picture
Figure 4. Antifungal Drugs Product Picture
Figure 5. Anti-Leishmanial/Antimicrobial Drugs Product Picture
Figure 6. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Application in 2020 & 2027
Figure 7. Hospital
Figure 8. Retail Pharmacy
Figure 9. Others
Figure 10. Cutaneous Leishmaniasis Drugs Report Years Considered
Figure 11. Global Cutaneous Leishmaniasis Drugs Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Cutaneous Leishmaniasis Drugs Market Size 2016-2027 (US$ Million)
Figure 13. Global Cutaneous Leishmaniasis Drugs Sales 2016-2027 (K Units)
Figure 14. Global Cutaneous Leishmaniasis Drugs Market Size Market Share by Region: 2021 Versus 2027
Figure 15. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Region (2016-2021)
Figure 16. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Region in 2020
Figure 17. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Region (2016-2021)
Figure 18. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Region in 2020
Figure 19. Global Cutaneous Leishmaniasis Drugs Sales Share by Manufacturer in 2020
Figure 20. The Top 10 and 5 Players Market Share by Cutaneous Leishmaniasis Drugs Revenue in 2020
Figure 21. Cutaneous Leishmaniasis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 22. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Type (2016-2021)
Figure 23. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Type in 2020
Figure 24. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Type (2016-2021)
Figure 25. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Type in 2020
Figure 26. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Application (2016-2021)
Figure 27. Global Cutaneous Leishmaniasis Drugs Sales Market Share by Application in 2020
Figure 28. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Application (2016-2021)
Figure 29. Global Cutaneous Leishmaniasis Drugs Revenue Market Share by Application in 2020
Figure 30. China Cutaneous Leishmaniasis Drugs Sales Growth Rate 2016-2027 (K Units)
Figure 31. China Cutaneous Leishmaniasis Drugs Revenue Growth Rate 2016-2027 (US$ Million)
Figure 32. China Cutaneous Leishmaniasis Drugs Market Share in Global Market 2016-2027
Figure 33. China 5 and 10 Largest Cutaneous Leishmaniasis Drugs Players Market Share by Revenue in Cutaneous Leishmaniasis Drugs in 2020
Figure 34. China Cutaneous Leishmaniasis Drugs Revenue Share by Type (2016-2021)
Figure 35. China Cutaneous Leishmaniasis Drugs Revenue Growth Rate by Type in 2016 & 2020
Figure 36. China Cutaneous Leishmaniasis Drugs Revenue Share by Application (2016-2021)
Figure 37. China Cutaneous Leishmaniasis Drugs Revenue Growth Rate by Application in 2016 & 2020
Figure 38. North America Cutaneous Leishmaniasis Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 39. North America Cutaneous Leishmaniasis Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 40. North America Cutaneous Leishmaniasis Drugs Sales Market Share by Country in 2020
Figure 41. North America Cutaneous Leishmaniasis Drugs Revenue Market Share by Country in 2020
Figure 42. United States Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 43. United States Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Canada Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 45. Canada Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Europe Cutaneous Leishmaniasis Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 47. Europe Cutaneous Leishmaniasis Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 48. Europe Cutaneous Leishmaniasis Drugs Sales Market Share by Country in 2020
Figure 49. Europe Cutaneous Leishmaniasis Drugs Revenue Market Share by Country in 2020
Figure 50. Germany Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 51. Germany Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 52. France Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 53. France Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 54. U.K. Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 55. U.K. Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 56. Italy Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 57. Italy Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 58. Russia Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 59. Russia Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 60. Asia Pacific Cutaneous Leishmaniasis Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 61. Asia Pacific Cutaneous Leishmaniasis Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 62. Asia Pacific Cutaneous Leishmaniasis Drugs Sales Market Share by Region in 2020
Figure 63. Asia Pacific Cutaneous Leishmaniasis Drugs Revenue Market Share by Region in 2020
Figure 64. China Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 65. China Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 66. Japan Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 67. Japan Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 68. South Korea Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 69. South Korea Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 70. India Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 71. India Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 72. Australia Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 73. Australia Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 74. China Taiwan Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 75. China Taiwan Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 76. Indonesia Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 77. Indonesia Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 78. Thailand Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 79. Thailand Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 80. Malaysia Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 81. Malaysia Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 82. Latin America Cutaneous Leishmaniasis Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 83. Latin America Cutaneous Leishmaniasis Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 84. Latin America Cutaneous Leishmaniasis Drugs Sales Market Share by Country in 2020
Figure 85. Latin America Cutaneous Leishmaniasis Drugs Revenue Market Share by Country in 2020
Figure 86. Mexico Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 87. Mexico Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 88. Brazil Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 89. Brazil Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 90. Argentina Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 91. Argentina Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 92. Colombia Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 93. Colombia Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 94. Middle East and Africa Cutaneous Leishmaniasis Drugs Sales Growth Rate 2016-2021 (K Units)
Figure 95. Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue Growth Rate 2016-2021 (US$ Million)
Figure 96. Middle East and Africa Cutaneous Leishmaniasis Drugs Sales Market Share by Country in 2020
Figure 97. Middle East and Africa Cutaneous Leishmaniasis Drugs Revenue Market Share by Country in 2020
Figure 98. Turkey Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 99. Turkey Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 100. Saudi Arabia Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 101. Saudi Arabia Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 102. UAE Cutaneous Leishmaniasis Drugs Sales Growth Rate (2016-2021) (K Units)
Figure 103. UAE Cutaneous Leishmaniasis Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 104. Cutaneous Leishmaniasis Drugs Value Chain
Figure 105. Channels of Distribution
Figure 106. Distributors Profiles
Figure 107. Bottom-up and Top-down Approaches for This Report
Figure 108. Data Triangulation
Figure 109. Key Executives Interviewed
エクセナチド薬の世界市場 2020年 Market Overview The global Exenatide Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Exenatide Drugs market report…- ニボルマブ薬の世界市場 2020年 Market Overview The Nivolumab Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade…
- テデュグルチド薬の世界市場 2020年 Market Overview The global Teduglutide Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Teduglutide Drugs market re…
- アンチエイジング薬の世界及び中国市場 Botox and filler treatments are into the drift. Botox encompasses purified bacteria that freezes muscles. In doing so, Botox can help minimalize the appearance of wrinkles and lines caused by facial fillers and expressions contain elements that add plumpness to areas that have thinned due to aging. …
- 動物用抗感染薬の世界市場 2020年 Market Overview The Anti-infective Drugs for Animals market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain op…